NCT00253513 · OUTCOME

Number of Patients Experiencing Regimen-related Toxicity Events in Study Population

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome · Source last updated 2012-06-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: 34 days and 2 years

What was measured

Proportion of patients experiencing regimen-related toxicity to major organ systems from day minus 6 to day 28. Major organ systems: cardiac, bladder/renal, pulmonary, hepatic, neurologic and gastrointestinal

Groups in this outcome

Treosulfan and Fludarabine Conditioning

Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treosulfan and Fludarabine Conditioning	60

Reported measurements

Severe Regimen Related Toxicity (RRT)

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treosulfan and Fludarabine Conditioning	2	Not reported	Not reported	Not reported	Not reported

Nonrelapse mortality at 2 years

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treosulfan and Fludarabine Conditioning	5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
2
title
Severe Regimen Related Toxicity (RRT)
categories
measurements
group Id
OG000
value
5
title
Nonrelapse mortality at 2 years

denoms

counts
group Id
OG000
value
60
units
Participants

description

groups

description
Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
id
OG000
title
Treosulfan and Fludarabine Conditioning

param Type

NUMBER

reporting Status

POSTED

time Frame

34 days and 2 years

title

Number of Patients Experiencing Regimen-related Toxicity Events in Study Population

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice